Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
As of today, Gilead Sciences(GILD) shares are valued at $124.29. The company's market cap stands at 154.27B, with a P/E ratio of 18.81 and a dividend yield of 2.6%.
On 2025-12-19, Gilead Sciences(GILD) stock traded between a low of $120.68 and a high of $126.27. Shares are currently priced at $124.29, which is +3.0% above the low and -1.6% below the high.
The Gilead Sciences(GILD)'s current trading volume is 24.11M, compared to an average daily volume of 7.47M.
During the past year, Gilead Sciences(GILD) stock moved between $88.57 at its lowest and $128.70 at its peak.
During the past year, Gilead Sciences(GILD) stock moved between $88.57 at its lowest and $128.70 at its peak.
GILD News
Gilead (GILD) Sciences announced an agreement with the U.S. government designed to reduce drug costs for Americans. “This agreement reflects a foundational comm...
Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. Biktarvy sales and Descovy for pre-exposure...
Gilead Sciences recently reported that its Phase 3 ARTISTRY-2 trial showed a once-daily bictegravir/lenacapavir pill matched Biktarvy in maintaining HIV viral s...
Analyst ratings
72%
of 29 ratingsMore GILD News
Gilead (GILD) announced that Keeley Wettan will be appointed executive VP, general counsel, legal and compliance effective immediately. She will join the compan...
If you are wondering whether Gilead Sciences is still a smart consideration after its big run, or if you are late to the party, this breakdown will help you ass...
Below is Validea's guru fundamental report for GILEAD SCIENCES, INC. (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Earnings Yield In...
In a report released today, Joseph Stringer from Needham maintained a Buy rating on Gilead Sciences, with a price target of $140.00. Claim 50% Off TipRanks Prem...
(RTTNews) - Gilead Sciences (GILD) on Monday reported positive topline results from the Phase 3 ARTISTRY-2 trial. This trial looked at switching from BIKTARVY...